Cellular Genomics's cutting-edge approach is based on the discovery of Analog Sensitive Kinase Alleles (ASKAs).
What does ASKA stand for?
ASKA stands for Analog Sensitive Kinase Allele (immunology)
This definition appears somewhat frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of ASKA
We have 2 other meanings of ASKA in our Acronym Attic
- Available Seat Kilometre
- Awareness, Skill and Knowledge
- Yamoussoukro, Cote d'Ivoire (airport code)
- Ambient Intelligence System of Agents for Knowledge-Based and Integrated Services for Mobility Impaired Users
- Apoptosis Signal-Regulating Kinase 1
- Arabidopsis Serine/Threonine Kinase1
- Assessment System for K-12
- Amateur Shotokan Karate Association (martial arts)
- American Shotokan Karate Academy (various locations)
- American Shotokan Karate Alliance (St. Peters, MO)
- Anti-Slipknot Army
- Arizona State Karate Alliance (Phoenix, AZ)
- Australasian Square Kilometre Array Consortium
- Australian Square Kilometre Array Pathfinder (radio telescope)
- Alexander Skarsgard (actor)
- Aviation Storage Kitting and Retrieval System
- Aging Sexuality Knowledge and Attitudes Scale
- Air Superiority Knowledge Assessment System (US DoD)
- Alice Springs Kennel Club, Inc. (Australia)
- Association of Scottish Kart Clubs (UK)
Samples in periodicals archive:
CGI), a chemical genetics based biopharmaceutical company, today announced that it has entered into a research collaboration with Eli Lilly and Company, under which CGI will apply its chemical genetics Analog Sensitive Kinase Allele (ASKA) technology to the study of kinase drug targets selected by Lilly.
CGI's cutting-edge chemical genetics approach is based on the discovery of Analog Sensitive Kinase Alleles (ASKAs).
6390821, titled "Engineered protein kinases which can utilize modified nucleotide triphosphate substrates," is based upon the breakthrough discovery of Analog Sensitive Kinase Alleles, or ASKAs.
Through the application of functionally intact and pharmacologically inhibitable analog sensitive kinase alleles (ASKAs) and proprietary P-Target(TM) and P-Inhibitor(TM) platforms, this broadly enabling chemical genetic technology has been applied to protein kinases, an important class of drug targets across multiple clinical indications, including cancer, inflammatory, and autoimmune diseases.